Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
GLUT8
is a novel glucose transporter protein that is widely distributed in tissues including liver, a central organ of regulation of glucose homeostasis. The purpose of the current study was to investigate expression and regulation of hepatic
GLUT8
mRNA and protein. Therefore, Northern and immunoblot analysis, semiquantitative RT-PCR, and immunofluorescence microscopy were performed using mouse livers at different stages of embryonic and postnatal development and in type 1 (streprozotocin treated) and type 2 (GLUT4 heterozygous) diabetes.
GLUT8
mRNA and protein expression in embryonic liver was differentially regulated depending on the prenatal and postnatal developmental stage of the mice. Immunofluorescence microscopy of liver from wild-type mice demonstrated the highest levels of
GLUT8
protein in perivenous hepatocytes pointing to its role in regulation of glycolytic flux. In diabetic scenarios,
GLUT8
mRNA levels were correlated with circulating insulin; specifically,
GLUT8
mRNA decreased in a
type 1 diabetes
model and increased in a type 2 diabetes model, suggesting a regulatory role for insulin in
GLUT8
mRNA expression. While up-regulation of
GLUT8
protein occurred in both models of diabetes, only in streptozotocin diabetic livers was
GLUT8
zonation altered. These data demonstrate that
GLUT8
mRNA and protein are differentially regulated in liver in response to physiologic and pathologic (diabetes) milieu and suggests that
GLUT8
is intimately linked to glucose homeostasis.
...
PMID:Regulation of hepatic GLUT8 expression in normal and diabetic models. 1269 74
Disease states such as diabetes mellitus are known to impair hippocampal glucoregulatory activities, which may contribute to cognitive deficits observed in diabetic subjects. Stress or exposure to stress levels of glucocorticoids (GCs) are also intimately involved in hippocampal glucoregulatory activities and the actions of GCs are often most evident in hyperglycemic states. Glucose transporter (GLUT) expression, activity and translocation represent components of the glucoregulatory activities of the hippocampus that may be disrupted by diabetes and stress. Accordingly, the current study examined the effects of stress, streptozotocin (STZ)-induced diabetes and the combined actions of stress and hyperglycemia upon
GLUT8
mRNA expression, protein levels and intracellular trafficking in the rat hippocampus. Short-term stress in euglycemic rats had no effect upon
GLUT8
mRNA, while restraint stress normalized diabetes mediated increases in
GLUT8
mRNA expression in STZ treated rats. Radioimmunocytochemical analysis revealed that total
GLUT8
protein levels were not altered by diabetes, short-term stress or the combined actions of hyperglycemia and stress. However, subcellular compartmentalization of
GLUT8
was modulated by stress in that hippocampal
GLUT8
protein levels were increased in high-density microsomal (HDM) fractions isolated from rats subjected to stress. In contrast, STZ-diabetes decreased
GLUT8
protein levels in the HDM fraction, an effect that was potentiated by stress. Collectively, these results demonstrate that the actions of GCs may be dramatically different in euglycemic and hyperglycemic/insulinopenic states, suggesting that stress may increase hippocampal neuronal responsiveness under normal physiological conditions while increasing hippocampal neuronal vulnerability in pathophysiological settings such as in
type 1 diabetes
.
...
PMID:Biphasic effects of stress upon GLUT8 glucose transporter expression and trafficking in the diabetic rat hippocampus. 1504 21
Heart consumes more energy than any other organ. It can utilize various metabolic substrates as a source of energy. The primary substrates are free fatty acids, especially long-chain fatty acids and glucose. The lipid bilayer of plasmalemma is impermeable for glucose. Therefore, glucose transport across the plasma membrane is mediated via glucose transporters. In human, cardiac cells are expressed as 2 families of glucose transporters: GLUTs and SGLTs. These transport proteins are GLUT1, GLUT3,
GLUT8
, GLUT10, GLUT11, GLUT12 and SGLT1. In human heart, GLUT4 is the major isoform that represents approximately 70% of the total glucose transporters. The changes observed in diabetic heart showed that
type 1 diabetes
mellitus alters the expression and translocation of GLUT4 and
GLUT8
in the atria. In diabetic atria, the content in cell surface of these glucose transporters is downregulated. Expression of SGLT1, is increased in patients with end-stage cardiomyopathy secondary to type 2 diabetes. Increased expression of SGLT1 is a compensatory mechanism to the reduction in cardiac GLUT1 and GLUT4 expression. In animal model of
type 1 diabetes
, the expression of Sglt1 transporter is significantly decreased, and in the animal model of type 2 diabetes it is significantly increased. In heart diseases, such as cardiac hypertrophy (that is similar to fetal heart), heart failure and myocardial ischemia different perturbations in expression of glucose transporters are observed, especially in GLUT1 and GLUT4, due to changes in heart glucose metabolism. In this article, the functions of glucose transporters in healthy heart and in cardiac diseases are reviewed.
...
PMID:Glucose transporters in healthy heart and in cardiac disease. 2803 63
Preimplantation embryos are sensitive to maternal hormones affecting embryonic signal transduction and metabolic functions. We examined whether adiponectin, the most abundantly secreted adipokine, can influence glucose transport in mouse embryonic cells. In mouse blastocysts full-length adiponectin stimulated glucose uptake, while no effect of globular adiponectin was found. Full-length adiponectin stimulated translocation of
GLUT8
glucose transporter to the cell membrane; we did not detect significant changes in the intracellular localization of GLUT4 glucose transporter in adiponectin-treated blastocysts. To study adiponectin signaling in detail, we used embryoid bodies formed from mouse embryonic carcinoma cell (ECC) line P19. We confirmed the expression of adiponectin receptors in these cells. Similar to mouse blastocysts, full-length adiponectin, but not globular adiponectin, stimulated glucose uptake in ECC P19 embryoid bodies. Moreover, full-length adiponectin stimulated AMPK and p38 MAPK phosphorylation. These results indicate that besides AMPK, p38 MAPK is a potential target of adiponectin in mouse embryonic cells. AMPK inhibitor did not influence the adiponectin-stimulated p38 MAPK phosphorylation, indicating independent action of these two signaling pathways. In mouse embryos adiponectin acts as a hormonal regulator of glucose uptake, which becomes especially important in phases with reduced levels of circulating insulin. Our results suggest that adiponectin maintains the glucose supply for early embryos under hypoinsulinaemic conditions, for example, in mothers suffering from
type 1 diabetes
mellitus.
...
PMID:Adiponectin stimulates glucose uptake in mouse blastocysts and embryonic carcinoma cells. 3202 7